Table 3.
Multivariate Analysis of outcomes
| NRM | Relapse | PFS | OS | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) |
p-value | HR (95% CI) |
p-value | HR (95% CI) |
p-value | HR (95% CI) |
p-value | |
| RI | 0·22 | 0·2 | ||||||
| Normal/Mild | 1 | 1 | 1 | 1 | ||||
| Moderate | 1·3 (0·6-3·2) |
0·5 | 0·8 (0·7-1) |
0·09 | 0·8 (0·7-1) |
0·06 | 0·9 (0·7-1·2) |
0·4 |
| Severe | 2·5 (0·9-7·1) |
0·09 | 0·9 (0·6-1·2) |
0·5 | 0·8 (0·6-1·2) |
0·3 | 0·9 (0·5-1·3) |
0·5 |
| Ig subtype | NS | 0·01 | NS | <0·0001 | ||||
| IgG subtype (N=830) | 1 | 1 | ||||||
| IgA subtype (N=289) | 1·2 (1·0-1·5) |
0·03 | 1·6 (1·2-2) |
<0·0001 | ||||
| Light chain (N=311) | 0·9 (0·7-1) |
0·09 | 0·8 (0·6-1) |
0·07 | ||||
| Non-secretory/others (N=48) | 1·1 (0·8-1·6) |
0·6 | 1 (0·6-1·8) |
0·9 | ||||
| ISS at diagnosis, III vs others | NS | 1·5 (1·3-1·7) |
<0·0001 | 1·4 (1·2-1·7) |
<0·0001 | 1·9 (1·6-2·4) |
<0·0001 | |
| Lines of chemotherapy ≥2 vs 1 | NS | 1·3 (1·1-1·5) |
0·007 | 1·2 (1·1-1·5) |
0·009 | 1·4 (1·1-1·7) |
0·009 | |
| Chemo-sensitivity versus chemo-resistant | NS | 0·6 (0·5-0·8) |
<0·0001 | 0·6 (0·5-0·8) |
<0·0001 | 0·6 (0·5-0·9) |
0·007 | |
| Planned post-transplant treatment, no versus yes | NS | 1·6 (1·4-1·8) |
<0·0001 | 1·6 (1·4-1·8) |
<0·0001 | 2 (1·6-2·5) |
<0·0001 | |
NRM, non-relapse mortality; PFS, progression-free survival; OS, overall survival; CI, confidence interval; NS, not significant; Ig, immunoglobulin; ISS, International Staging System